期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/ijms232113171
关键词
Alzheimer's disease; inflammation; non-coding RNAs; exosome vesicles
资金
- Pla Propi UJI [B2021-21]
- University of Naples Federico II, Ricerca Dipartimentale
- University of Naples Federico II
Neuroinflammation plays a major role in the onset of Alzheimer's Disease (AD), and it exerts its toxic effect through regulation of non-coding RNAs such as miRNAs. Although the association between miRNAs and inflammation in AD has been studied, the role of long non-coding RNAs (lncRNAs) in neurodegenerative diseases is less explored. Recent studies have shown that specific lncRNAs in plasma-isolated extracellular vesicles (EVs) may serve as reliable biomarkers for AD, which holds promise for improving risk prediction and patient stratification.
Alzheimer's Disease (AD) has currently no effective treatment; however, preventive measures have the potential to reduce AD risk. Thus, accurate and early prediction of risk is an important strategy to alleviate the AD burden. Neuroinflammation is a major factor prompting the onset of the disease. Inflammation exerts its toxic effect via multiple mechanisms. Amongst others, it is affecting gene expression via modulation of non-coding RNAs (ncRNAs), such as miRNAs. Recent evidence supports that inflammation can also affect long non-coding RNA (lncRNA) expression. While the association between miRNAs and inflammation in AD has been studied, the role of lncRNAs in neurodegenerative diseases has been less explored. In this review, we focus on lncRNAs and inflammation in the context of AD. Furthermore, since plasma-isolated extracellular vesicles (EVs) are increasingly recognized as an effective monitoring strategy for brain pathologies, we have focused on the studies reporting dysregulated lncRNAs in EVs isolated from AD patients and controls. The revised literature shows a positive association between pro-inflammatory lncRNAs and AD. However, the reports evaluating lncRNA alterations in EVs isolated from the plasma of patients and controls, although still limited, confirm the value of specific lncRNAs associated with AD as reliable biomarkers. This is an emerging field that will open new avenues to improve risk prediction and patient stratification, and may lead to the discovery of potential novel therapeutic targets for AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据